

The United States of America



The Commissioner of Patents and Trademarks

Has received an application for a patent for a new and useful invention. The title and description of the invention are enclosed. The requirements of law have been complied with, and it has been determined that a patent on the invention shall be granted under the law.

Therefore, this

United States Patent

Grants to the person(s) having title to this patent the right to exclude others from making, using, offering for sale, or selling the invention throughout the United States of America or importing the invention into the United States of America for the term set forth below, subject to the payment of maintenance fees as provided by law.

If this application was filed prior to June 8, 1995, the term of this patent is the longer of seventeen years from the date of grant of this patent or twenty years from the earliest effective U.S. filing date of the application, subject to any statutory extension.

If this application was filed on or after June 8, 1995, the term of this patent is twenty years from the U.S. filing date, subject to any statutory extension. If the application contains a specific reference to an earlier filed application or applications under 35 U.S.C. 120, 121 or 365(c), the term of the patent is twenty years from the date on which the earliest application was filed, subject to any statutory extension.

J. Todd Johnson

Acting Commissioner of Patents and Trademarks

Margaret V. Turner

Attest



US005888552A

United States Patent [19]

Bounous et al.

[11] Patent Number: 5,888,552

[45] Date of Patent: Mar. 30, 1999

[54] ANTI-CANCER THERAPEUTIC COMPOSITIONS CONTAINING WHEY PROTEIN CONCENTRATE

[75] Inventors: Gustavo Bounous, Montreal, Phil Gold, Westmount, both of Canada

[73] Assignee: Immunotec Research Corporation Ltd., Quebec, Canada

[21] Appl. No.: 381,975

[22] PCT Filed: Aug. 5, 1993

[86] PCT No.: PCT/CA93/00309

§ 371 Date: May 8, 1995

§ 102(e) Date: May 8, 1995

[87] PCT Pub. No.: WO94/04168

PCT Pub. Date: Mar. 3, 1994

Related U.S. Application Data

[63] Continuation-in-part of Ser. No. 929,347, Aug. 13, 1992, abandoned, and Ser. No. 806,756, Apr. 10, 1992, Pat. No. 5,456,924, which is a continuation-in-part of Ser. No. 417,246, Oct. 4, 1989, Pat. No. 5,290,571, which is a continuation-in-part of Ser. No. 289,071, Dec. 23, 1988, abandoned, which is a continuation-in-part of Ser. No. 188,276, Apr. 29, 1988, abandoned, said Ser. No. 929,347, is a continuation-in-part of Ser. No. 417,246.

[51] Int. Cl.⁶ A61K 35/20

[52] U.S. Cl. 424/535; 514/2; 514/21; 514/251; 514/276; 514/885; 530/365; 530/833; 426/72

[58] Field of Search 424/535; 514/2; 514/21; 251; 276; 885; 530/365; 833; 426/72

References Cited

U.S. PATENT DOCUMENTS

4,784,685 11/1988 Meister 504/110

FOREIGN PATENT DOCUMENTS

222560 5/1981 Argentina
1495940 12/1977 United Kingdom

OTHER PUBLICATIONS

Anderson, M.E., "Tissue glutathione," *C.R.C. Handbook of Methods for Oxygen Radical Research*, pp. 317-329 (1985) (Exhibit 1).

Lauterburg, B.H. et al., "Therapeutic doses of acetaminophen stimulate the turnover of cysteine and glutathione in man," *J. Hepatol.*, vol. 4, pp. 206-211 (1987) (Exhibit 2).

Lewis, A.D. et al., *Proc. Natl. Acad. Sci.*, vol. 85, pp. 8511-8515 (1988) (Exhibit 3).

Russo, A. et al., "Selective modulation of glutathione levels in human normal versus tumor cells and subsequent differential response to chemotherapy drugs," *Cancer Res.*, vol. 46, pp. 2865-2868 (1986) (Exhibit 4).

Wakita, P.J., "Dairy Chemistry and Physics," Wiley J. Nitro, (ed.), p. 106 (1984) (Exhibit 5).

Williamson, J.M. et al., "Intracellular cysteine delivery system that protects against toxicity by promoting GSH synthesis," *Proc. Natl. Acad. Sci. U.S.A.*, vol. 79, pp. 6246-6249 (1982) (Exhibit 6).

Bounous, G., et al., "Dietary Whey Protein Inhibits the Development of Dimethylhydrazine Induced Malignancy," *Clin. Invest. Med.*, (1980) vol. 11, pp. 231-237.

Papenburg, R., et al., "Dietary Milk Proteins Inhibit The Development of Dimethylhydrazine-Induced Malignancy," *Tumor Biology*, (1990) vol. 11, pp. 129-136.

Banchiel, S., et al., (1992) AACR Abstract, "Different Effects of OTZ on Organ GSH Levels in Rate Bearing Tumors".

John, A.M. et al., "Amino Acid Requirements of the Growing Mouse," *J. Nutr.*, (1976) vol. 106, pp. 1361-1367.

Hoag, W.G., et al., "Nutrition" In: *Biology of the Laboratory Mouse*, E.L. Green, (ed.), (McGraw-Hill, New York: 1966) pp. 39-43.

Cunningham, A., et al., "Further Improvements in the Plaque Technique for Detecting Single Antibody Forming Cells," *J. Immunol.*, (1968) vol. 14, pp. 559-600.

Anderson, M.E., "Tissue Glutathione" In: *Handbook of Methods for Oxygen Radical Research*, (C.R.C. Press, Boca Raton: 1988) pp. 317-329.

Glatt, H., et al., "Mutagenicity of Glutathione and Cysteine in the Ames Test," *Science*, (1983) vol. 220, pp. 961-962.

Taylor, Y.C., et al., "Elevation of Intracellular Glutathione Levels Following Depletion and its Relationship to Protection Against Radiation and Alkylating Agents," *Pharmacol. Ther.*, (1988) vol. 39, pp. 293-299.

White, C.W., et al., "Hypoxia Increases Glutathione Redox Cycle and Protects Rat Lungs Against Oxidants," *J. Appl. Physiol.*, (1988) vol. 65, pp. 2607-2616.

Anderson, M.E., et al., "Transport and Direct Utilization of Gamma-Glutamylcyst(e)ine for glutathione Synthesis," *Proc. Natl. Acad. Sci. U.S.A.*, (1983) vol. 80, pages 707-711.

Richie, J.P., et al., "Correction of a Glutathione Deficiency in the Aging Mosquito Increases its Longevity," *Proc. Soc. Exp. Biol. Med.*, (1987) vol. 184, pp. 113-117.

Fernandez-Checa, J.C., et al., "Effects of Chronic Ethanol Feeding on Rat Hepatocyte Glutathione," *J. Clin. Invest.*, (1989) vol. 83, pp. 1247-1252.

Meister, A., et al., "Glutathione," *Annu. Rev. Biochem.*, (1983) vol. 52, pp. 711-760.

Hamilton, T.C., et al., "Augmentation of Adriamycin, Melphalan and Cisplatin Cytotoxicity in Drug Resistant and Sensitive Human Ovarian Cancer Cell Lines by BSO Mediated GSH Depletion," *Biochem. Pharmacol.*, (1985) vol. 34, pp. 2583-2586.

(List continued on next page.)

Primary Examiner—Jean C. Witz
Attorney, Agent, or Firm—John P. White; Cooper & Dunham LLP

[57] ABSTRACT

This invention relates to a method of treatment of patients having lesions resulting from cancer cells and to an application as an anti-cancer composition of undenatured whey protein concentrate.

22 Claims, 3 Drawing Sheets